Addressing overtreatment of screen detected DCIS; The LORIS trial

European Journal of Cancer

Volumn 51, Issue 16, 2015, Pages 2296-2303

  Francis, Adele ^a   Thomas, Jeremy ^b   Fallowfield, Lesley ^c   Wallis, Matthew ^d   Bartlett, John M S ^e   Brookes, Cassandra ^f   Roberts, Tracy ^f   Pirrie, Sarah ^f   Gaunt, Claire ^f   Young, Jennie ^f   Billingham, Lucinda ^f   Dodwell, David ^g   Hanby, Andrew ^g   Pinder, Sarah E ^h   Evans, Andrew ⁱ   Reed, Malcolm ^c   Jenkins, Valerie ^c   Matthews, Lucy ^c   Wilcox, Maggie ^j   Fairbrother, Patricia ^j   Bowden, Sarah ^f   Rea, Daniel ^f   more..

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF DUNDEE   (United Kingdom)

^j Independent Cancer Patients' Voice   (United Kingdom)

more..

Author keywords

Breast cancer; Breast screening; Clinical trial; DCIS; Low grade DCIS; Over treatment

Indexed keywords

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; INTRADUCTAL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; TRANSLATIONAL RESEARCH; TUMOR BIOPSY; VACUUM ASSISTED CORE BIOPSY; BIOPSY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; HEALTH CARE COST; HEALTH SERVICE; MAMMOGRAPHY; MASTECTOMY; METHODOLOGY; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; UNITED KINGDOM; WATCHFUL WAITING;

BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MAMMOGRAPHY; MASTECTOMY; MEDICAL OVERUSE; NEOPLASM GRADING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; WATCHFUL WAITING;

EID: 84943662330     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.017     Document Type: Article

References (32)

1. Independent, U.K.P.O.B.C.S., The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380(9855): p. 1778-86.
2. N. Biller-Andorno Cancer detection: breast-screening trials are ethical Nature 511 7508 2014 155
3. P.C. Gotzsche, and K.J. Jorgensen The breast screening programme and misinforming the public J R Soc Med 104 9 2011 361 369
4. D.B. Kopans, R.A. Smith, and S.W. Duffy Mammographic screening and "overdiagnosis" Radiology 260 3 2011 616 620
5. CRUKwebsite, < http://www.cancerresearchuk.org/cancer/info/cancerstats/types/breast/Incidence-in-situ/ >.
6. Rothnie N, An audit of screen detected breast cancers for the year of screening 2011/12 2013, NHS Breast Screening Programme and association of Breast Surgeons.
7. CR-UKwebsite, > http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/ > [accessed 05.01.2014].
8. A.J. Evans, and et al. The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours Br J Cancer 75 4 1997 542 544
9. S.E. Pinder, and et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial Br J Cancer 103 1 2010 94 100
10. M.E. Brennan, and et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer Radiology 260 1 2011 119 128
11. Y.H. Yu, C. Liang, and X.Z. Yuan Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review Breast Cancer Res Treat 120 2 2010 469 479
12. W.L. Betsill Jr, and et al. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone JAMA 239 18 1978 1863 1867
13. L.C. Collins, and et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study Cancer 103 9 2005 1778 1784
14. M.E. Sanders, and et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up Cancer 103 12 2005 2481 2484
15. V. Eusebi, and et al. Long-term follow-up of in situ carcinoma of the breast Semin Diagn Pathol 11 3 1994 223 235
16. M. Dowsett, and et al. International Web-based consultation on priorities for translational breast cancer research Breast Cancer Res 9 6 2007 R81
17. A. Bombonati, and D.C. Sgroi The molecular pathology of breast cancer progression J Pathol 223 2 2011 307 317
18. P.T. Simpson, and et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis Am J Surg Pathol 29 6 2005 734 746
19. L. Wiechmann, and H.M. Kuerer The molecular journey from ductal carcinoma in situ to invasive breast cancer Cancer 112 10 2008 2130 2142
20. V.V. Iakovlev, and et al. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study Clin Cancer Res 14 14 2008 4446 4454
21. S. Steinman, and et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast Ann Clin Lab Sci 37 2 2007 127 134
22. L.J. Solin, and et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast J Natl Cancer Inst 105 10 2013 701 710
23. K. Kerlikowske, and et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis J Natl Cancer Inst 102 9 2010 627 637
24. Rakovitch E, et al., A large prospectively-designed study of the DCIS score: predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. San Antonio Breast Cancer Symposium, 2014. S5-04.
25. C.S. Carver You want to measure coping but your protocol's too long: consider the brief COPE Int J Behav Med 4 1 1997 92 100
26. L. Fallowfield, and et al. Time for a low-risk DCIS trial: harnessing public and patient involvement Lancet Oncol 13 12 2012 1183 1185
27. J.L. Donovan, and et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial J Clin Epidemiol 62 1 2009 29 36
28. J. Wade, and et al. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials Soc Sci Med 68 11 2009 2018 2028
29. L. Fallowfield, and et al. Low grade Ductal Carcinoma in situ (DCIS): how best to describe it? Breast 23 5 2014 693 696
30. A. Kearney, and et al. Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays BMJ Open 4 9 2014 e005874
31. E.A. Rakha, and et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis J Clin Oncol 28 1 2010 99 104
32. E.A. Rakha, and et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis J Clin Oncol 28 1 2010 99 104